BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9052754)

  • 1. DNA repair capacity and cisplatin sensitivity of human testis tumour cells.
    Köberle B; Grimaldi KA; Sunters A; Hartley JA; Kelland LR; Masters JR
    Int J Cancer; 1997 Mar; 70(5):551-5. PubMed ID: 9052754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients.
    Hill BT; Scanlon KJ; Hansson J; Harstrick A; Pera M; Fichtinger-Schepman AM; Shellard SA
    Eur J Cancer; 1994; 30A(6):832-7. PubMed ID: 7917544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines.
    Bedford P; Fichtinger-Schepman AM; Shellard SA; Walker MC; Masters JR; Hill BT
    Cancer Res; 1988 Jun; 48(11):3019-24. PubMed ID: 3365691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours.
    Köberle B; Masters JR; Hartley JA; Wood RD
    Curr Biol; 1999 Mar; 9(5):273-6. PubMed ID: 10074455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines.
    Burger H; Nooter K; Boersma AW; Kortland CJ; Stoter G
    Int J Cancer; 1997 Nov; 73(4):592-9. PubMed ID: 9389577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated X-irradiation.
    Hill BT; Shellard SA; Hosking LK; Fichtinger-Schepman AM; Bedford P
    Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):75-83. PubMed ID: 2380098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity of testis tumour cells to chemotherapeutic drugs: role of detoxifying pathways.
    Masters JR; Thomas R; Hall AG; Hogarth L; Matheson EC; Cattan AR; Lohrer H
    Eur J Cancer; 1996 Jun; 32A(7):1248-53. PubMed ID: 8758261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypersensitivity of human testis-tumour cell lines to chemotherapeutic drugs.
    Masters JR; Osborne EJ; Walker MC; Parris CN
    Int J Cancer; 1993 Jan; 53(2):340-6. PubMed ID: 8425772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of the unusual expression of cross resistance to cisplatin in a series of etoposide-selected resistant sublines of the SuSa testicular teratoma cell line.
    Shellard SA; Hosking LK; Hill BT
    Biochem Pharmacol; 1994 Mar; 47(5):775-9. PubMed ID: 8135853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
    Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA repair in cisplatin-sensitive and resistant human cell lines measured in specific genes by quantitative polymerase chain reaction.
    Köberle B; Payne J; Grimaldi KA; Hartley JA; Masters JR
    Biochem Pharmacol; 1996 Dec; 52(11):1729-34. PubMed ID: 8986135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic basis of drug sensitivity in human testis tumour cells.
    Wang X; Hafezparast M; Masters JR
    Int J Cancer; 1996 Feb; 65(4):426-31. PubMed ID: 8621221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin.
    Cenni B; Kim HK; Bubley GJ; Aebi S; Fink D; Teicher BA; Howell SB; Christen RD
    Br J Cancer; 1999 May; 80(5-6):699-704. PubMed ID: 10360646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
    Li L; Keating MJ; Plunkett W; Yang LY
    Mol Pharmacol; 1997 Nov; 52(5):798-806. PubMed ID: 9351970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevation of XPA protein level in testis tumor cells without increasing resistance to cisplatin or UV radiation.
    Köberle B; Roginskaya V; Zima KS; Masters JR; Wood RD
    Mol Carcinog; 2008 Aug; 47(8):580-6. PubMed ID: 18240296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repair.
    Fenske AE; Glaesener S; Bokemeyer C; Thomale J; Dahm-Daphi J; Honecker F; Dartsch DC
    Cancer Lett; 2012 Nov; 324(2):171-8. PubMed ID: 22613583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of p53, Bcl-2 and Bax in cisplatin-induced apoptosis in testicular germ cell tumour cell lines.
    Burger H; Nooter K; Boersma AW; Kortland CJ; Stoter G
    Br J Cancer; 1998 May; 77(10):1562-7. PubMed ID: 9635829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
    Shellard SA; Hosking LK; Hill BT
    Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines.
    Hill BT; Shellard SA; Fichtinger-Schepman AM; Schmoll HJ; Harstrick A
    Anticancer Drugs; 1994 Jun; 5(3):321-8. PubMed ID: 7919457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
    O'Neill CF; Koberle B; Masters JR; Kelland LR
    Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.